BackChugai Pharmaceutical , Ltd. Overview

Chugai Pharmaceutical , Ltd. Receivables

Chugai Pharmaceutical , Ltd.'s receivables is $380B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$379.14B
↑ 19.70% YoYΔ $62.39B vs prior year quarter

Peer trimmed avg / median

Loading

Chugai Pharmaceutical , Ltd. Receivables History

Loading

Chugai Pharmaceutical , Ltd. vs. peers: Receivables Comparison

Loading

Chugai Pharmaceutical , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Chugai Pharmaceutical , Ltd. (4519.T) FAQ

As of the most recent data (June 2026), 4519.T shows a receivables of $380B. That compares with $320B in the prior-year period — up 19.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4519.T's receivables is now $380B (was $320B) — a 19.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Chugai Pharmaceutical , Ltd. is outperforming or lagging.

Tracking 4519.T's receivables over time shows whether Chugai Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $380B That compares with $320B in the prior-year period — up 19.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Chugai Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $380B) with ownership activity and broader fundamentals.